The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.
The firm has a 180-day grace period in which to regain compliance, by maintaining a $1.00 minimum closing bid price for at least 10 consecutive business days.
The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
The partners will codevelop software for both small and large variant detection and Illumina will create hardware-accelerated versions for its Dragen platform.
Last week, GenomeWeb readers were most interested in Illumina's plan to lay off 58 employees in California and in funding for a new human genome reference program.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
The results of the study, which involved more than 47,000 MS patients and 68,000 unaffected controls, explain almost half of the disease's estimated heritability.
Euformatics, EMQN, and GenQA will extend prior work on the development of an external quality assessment technical scheme for NGS-based clinical testing.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
Researchers from Wellcome Sanger Institute and elsewhere found that the immune landscape of the kidney is zoned to counter dominant immunological challenges.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
